Clinical Presentation, Diagnosis, and Genetic Characteristics of Patients with Hypophosphatemic Rickets

Yıl 2025, Cilt: 51 Sayı: 2, 193 - 200, 28.08.2025

Yasemin Denkboy Ongen , Şehime G Temel , Ömer Tarım , Şebnem Özemri Sağ , Erdal Eren

https://doi.org/10.32708/uutfd.1653471

Öz

Phosphate plays an essential role in bone mineralization. Hypophosphatemic rickets (HR) is a rare phosphate-wasting disorder that leads to rickets, which may be FGF23-dependent or independent. In this study, we aimed to evaluate the clinical features of HR patients with genotypic and phenotypic features. This study included 32 children. The suspected gene was primarily studied in cases meeting the clinical diagnosis. Variants were evaluated according to ACMG criteria. All HR patients' median ages at the onset of complaints and diagnosis were 1.5 and 5 years, respectively (p<0.001). The most common complaint is bowlegs. At the time of diagnosis, calcium was 9.70 mg/dl; phosphorus was 2.68±0.64 mg/dl; ALP was 530±245 u/l, PTH was 58.70 ng/l, tubular phosphate reabsorption was 74±17%, and TmP/GFR was 2.58±1.15. Five of 32 patients were diagnosed with McCune-Albright syndrome, and two patients were followed as HR secondary to chemotherapy. Variants of the PHEX gene were identified in 15 cases (X-linked HR). In X-linked HR patients, no statistically significant difference was found between the age of presentation and diagnosis. Diagnostic delay was observed in infantile hypercalcemia type 2 and hereditary HR with hypercalciuria patients who were followed with nephrocalcinosis from an early age. In conclusion, HR is rare, and patients with bowlegs, short stature, kidney stones, hypophosphatemia, and renal phosphate wasting should be classified as FGF-23 dependent or FGF-23 independent of initiating treatment as soon as possible. Delayed diagnosis is common in cases of nephrocalcinosis, so measurement of calcium and phosphate levels should be standard for these patients.

Anahtar Kelimeler

Hypophosphatemic rickets , McCune Albright Syndrome , PHEX , SLC34A3 , SLC34A1

Etik Beyan

The study was ethically approved by the local ethics committee (Approval number 2021-17/28) and conducted following the Declaration of Helsinki. The patient's parents had signed informed written consent.

Destekleyen Kurum

n/a

Teşekkür

Special thanks to Prof. Serap Demircioğlu for the genetic analysis of our twin HPR patient.

Hipofosfatemik Rikets Hastalarının Klinik Başvuru, Tanı ve Genetik Özellikleri

Öz

Fosfat kemik mineralizasyonunda önemli bir rol oynar. Hipofosfatemik rikets (HR), FGF23'e bağlı veya bağımsız olabilen riketse yol açan nadir bir fosfat kaybı bozukluğudur. Bu çalışmada, hipofosfatemik rikets hastalarının klinik özelliklerini genotip ve fenotipik özellikleriyle değerlendirmeyi amaçladık. Bu çalışmaya otuz iki hasta dâhil edildi. Klinik tanıyı karşılayan olgularda öncelikle şüpheli gen çalışıldı. Varyantlar ACMG kriterlerine göre değerlendirildi. Tüm HR hastalarının şikâyetlerin başlangıcındaki ve tanıdaki medyan yaşları sırasıyla 1,5 ve 5 yıl idi (p<0,001). En sık görülen şikâyet bacak eğriliğiydi. Tanı anında kalsiyum 9,70 mg/dl; fosfor 2,68±0,64 mg/dl; ALP 530±245 u/l, PTH 58,70 ng/l, tübüler fosfat reabsorbsiyonu %74±17 ve TmP/GFR 2,58±1,15 olarak bulundu. Otuz iki hastanın beşi McCune Albright sendromu tanısı aldı ve iki hasta kemoterapiye sekonder HR olarak takip edildi. On beş vakada PHEX gen varyantları saptandı (X’e bağlı HR). X’e bağlı HR hastalarında başvuru yaşı ile tanı yaşı arasında istatistiksel olarak anlamlı bir fark bulunmadı. Erken yaştan itibaren nefrokalsinozis ile takip edilen infantil hiperkalsemi tip 2 ve hiperkalsiürik herediter hipofosfatemik raşitizm hastalarında tanı gecikmesi gözlendi. Sonuç olarak hipofosfatemik raşitizm nadir görülür ve bacak eğriliği, boy kısalığı, böbrek taşı, hipofosfatemi ve renal fosfat kaybı olan hastalar mümkün olan en kısa sürede FGF-23 bağımlı veya FGF-23 bağımsız olarak sınıflandırılmalı ve tedavi planlanmalıdır. Nefrokalsinozis olgularında tanı gecikmesi sık görüldüğünden bu hastalarda kalsiyum ve fosfat düzeylerinin ölçümü standart olmalıdır.

Anahtar Kelimeler

Hipofosfatemik raşitizm , McCune Albright Sendromu , PHEX , SLC34A3 , SLC34A1

Kaynakça

• 1- Kritmetapak K, Kumar R. Phosphatonins: From Discovery to Therapeutics. Endocr Pract. 2023;29(1):69-79.
• 2- Imel EA. Congenital Conditions of Hypophosphatemia in Children. Calcif Tissue Int. 2021;108(1):74-90.
• 3- Şıklar Z, Turan S, Bereket A, et al. Nationwide Turkish Cohort Study of Hypophosphatemic Rickets. J Clin Res Pediatr Endocrinol. 2020;12(2):150-159.
• 4- Rafaelsen S, Johansson S, Ræder H, Bjerknes R. Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol. 2016;174(2):125-136.
• 5- Lambert AS, Zhukouskaya V, Rothenbuhler A, Linglart A. X-linked hypophosphatemia: Management and treatment prospects. Joint Bone Spine. 2019;86(6):731-738.
• 6- Rothenbuhler A, Schnabel D, Högler W, Linglart A. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). Metabolism. 2020;103S:153892.
• 7- Demir K, Özen S, Konakçı E, Aydın M, Darendeliler F. A comprehensive online calculator for pediatric endocrinologists: ÇEDD Çözüm/TPEDS Metrics. J Clin Res Pediatr Endocrinol 2017;9(2):182-184.
• 8- Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in medicine. 2015;17(5):405-23.
• 9- Capelli S, Donghi V, Maruca K, et al. Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets. Bone. 2015;79:143-149.
• 10- Demirbaş Ö, Eren E, Öngen YD, et al. A Novel PHEX Mutation in A Case Followed Up with A Diagnosis of X-linked Hypophosphatemic Rickets. J Curr Pediatr. 2023 Apr;21(1):98-101.
• 11- Guven A, Al-Rijjal RA, BinEssa HA, et al. Mutational analysis of PHEX, FGF23 and CLCN5 in patients with hypophosphataemic rickets. Clin Endocrinol (Oxf). 2017;87(1):103-112.
• 12- Eltan M, Alavanda C, Abali ZY, et al. Clinical and molecular genetic characteristics of patients with hereditary hypophosphatemia. J Clin Endocrinol Metab. Published online December 19, 2024.
• 13- Turan I, Erdem S, Kotan LD, et al. Experience with the targeted next-generation sequencing in the diagnosis of hereditary hypophosphatemic rickets. J Pediatr Endocrinol Metab. 2021;34(5):639-648. Published 2021 Apr 13. doi:10.1515/jpem-2020-0624.
• 14- Durmaz, Erdem et al. “Novel and de novo PHEX mutations in patients with hypophosphatemic rickets.” Bone vol. 52,1 (2013): 286-91.
• 15- Alikasifoglu A, Unsal Y, Gonc EN, Ozon ZA, Kandemir N, Alikasifoglu M. Long-term effect of conventional phosphate and calcitriol treatment on metabolic recovery and catch-up growth in children with PHEX mutation. J Pediatr Endocrinol Metab. 2021;34(12):1573-1584. Published 2021 Sep 16.
• 16- Acar S, BinEssa HA, Demir K, et al. Clinical and genetic characteristics of 15 families with hereditary hypophosphatemia: Novel Mutations in PHEX and SLC34A3. PLoS One. 2018;13(3):e0193388. Published 2018 Mar 5.
• 17- Boardman-Pretty F, Clift AK, Mahon H, Sawoky N, Mughal MZ. The Diagnostic Odyssey in Children and Adolescents With X-linked Hypophosphatemia: Population-Based, Case-Control Study. J Clin Endocrinol Metab. 2024;109(8):2012-2018.
• 18- Wu H, Ying H, Zhao W, et al. Characterization of Novel PHEX Variants in X-linked Hypophosphatemic Rickets and Genotype-PHEX Activity Correlation. J Clin Endocrinol Metab. 2024;109(9):2242-2255.
• 19- Bergwitz C, Miyamoto KI. Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis, and therapy. Pflugers Arch. 2019;471(1):149-163.
• 20- Imel EA, Glorieux FH, Whyte MP, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial [published correction appears in Lancet. 2019 Jul 13;394(10193):120.
• 21- Kamenický P, Briot K, Munns CF, Linglart A. X-linked hypophosphataemia. Lancet. 2024;404(10455):887-901. doi:10.1016/S0140-6736(24)01305-9.
• 22- Haffner, D., Emma, F., Seefried, L. et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol (2025).
• 23- US Food and Drug Administration. Crysvita (burosumab-twza) Marketing Approval.